Madrigal Pharmaceuticals, Inc. MDGL Cash, Cash Equivalents, Restricted Cash and Short-term Investments, At Cost
Other financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept mdgl:CashCashEquivalentsRestrictedCashAndShortTermInvestmentsAtCost.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s cash, cash equivalents, restricted cash and short-term investments, at cost.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s cash, cash equivalents, restricted cash and short-term investments, at cost?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported cash, cash equivalents, restricted cash and short-term investments, at cost of $818.17M in Q1 2026.